JPRN-UMIN000048100
Completed
未知
Durvalumab after chemoradiotherapy in non-small cell lung cancer harboring driver gene mutation/translocation: a retrospective multicenter study (HOT2101) - HOT2101
Hokkaido Lung Cancer Clinical Study Group(HOT)0 sites88 target enrollmentJune 20, 2022
Conditionsnon-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Hokkaido Lung Cancer Clinical Study Group(HOT)
- Enrollment
- 88
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who were deemed inappropriate for enrollment by investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patientsEUCTR2019-002537-11-FIOslo University Hospital100
Not yet recruiting
Phase 1/2
DART (19-14434)
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients2022-502640-12-01Oslo University Hospital Hf130
Active, not recruiting
Phase 1
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patientson-small cell lung cancer (NLCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002537-11-LTOslo University Hospital100
Completed
Phase 2
Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma. A multicenter, randomized, phase II trial of the German Anal Cancer Study GroupC21Malignant neoplasm of anus and anal canalDRKS00020739Goethe Universität; Universitätsklinikum Frankfurt Goethe-Universität180
Active, not recruiting
Phase 1
Radiochemotherapy +/- Durvalumab for locally-advanced Anal CarcinomaA multicenter, randomized, phase II trial of the German Anal Cancer Study Groupanal cancer (UICC-Stage IIB-IIIC, incl. T2>4cm Nany )MedDRA version: 21.1Level: PTClassification code 10002136Term: Anal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10002137Term: Anal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003005-25-ATniversity Hospital Frankfurt, Goethe University178